Figure 5. Rebastinib binding to endogenous CDK16 is confirmed by CETSA.

Aliquots of IGR-37 melanoma cells were treated with either rebastinib (20 µM) or vehicle (DMSO) and then heated for 3 min at indicated temperatures. CDK16 and GAPDH protein levels were then assessed by IB. Immunoreactive bands specific for CDK16 were confirmed using CDK16 knockdown cells; the middle band of the three observed was found to be non-specific (Supplementary Figure S1).